Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Busulfan, Fludarabine, Donor Stem Cell Transplant, and Cyclophosphamide in Treating Participants With Multiple Myeloma or Myelofibrosis

NCT03303950 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.

NCT NCT03303950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03303950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Busulfan, Fludarabine, Donor Stem Cell Transplant, and Cyclophosphamide in Treating Participants With Multiple Myeloma or Myelofibrosis
Lead sponsor
University of Utah
Phase
Phase 2
Overall status
Terminated
Start date
March 30, 2018
Completion date
February 19, 2020
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, asxl1 gene mutation, ezh2 gene mutation, idh1 gene mutation, idh2 gene mutation, plasma cell myeloma, primary myelofibrosis, recurrent plasma cell myeloma, secondary myelofibrosis, thrombocytopenia